Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. Hrkach J, et al. Among authors: sweeney c. Sci Transl Med. 2012 Apr 4;4(128):128ra39. doi: 10.1126/scitranslmed.3003651. Sci Transl Med. 2012. PMID: 22491949
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
Ravi P, Xie W, Buyse M, Halabi S, Kantoff PW, Sartor O, Attard G, Clarke N, D'Amico A, Dignam J, James N, Fizazi K, Gillessen S, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ. Ravi P, et al. Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024.04.038. Online ahead of print. Eur Urol. 2024. PMID: 38777647
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA. Pettersson A, et al. Among authors: sweeney c. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509. doi: 10.1158/1055-9965.EPI-12-0042. Epub 2012 Jun 26. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22736790 Free PMC article.
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.
Xie W, Ravi P, Buyse M, Halabi S, Kantoff P, Sartor O, Soule H, Clarke N, Dignam J, James N, Fizazi K, Gillessen S, Mottet N, Murphy L, Parulekar W, Sandler H, Tombal B, Williams S, Sweeney CJ. Xie W, et al. Among authors: sweeney cj. Ann Oncol. 2024 Mar;35(3):285-292. doi: 10.1016/j.annonc.2023.11.017. Epub 2023 Dec 5. Ann Oncol. 2024. PMID: 38061427
A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
Choudhury AD, Gray KP, Supko JG, Harshman LC, Taplin ME, Pace AF, Farina M, Zukotynski KA, Bernard B, Kantoff PW, Pomerantz M, Sweeney C. Choudhury AD, et al. Among authors: sweeney c. Prostate. 2018 Jun 7:10.1002/pros.23662. doi: 10.1002/pros.23662. Online ahead of print. Prostate. 2018. PMID: 29882250 Free PMC article.
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib.
Tripathi A, Supko JG, Gray KP, Melnick ZJ, Regan MM, Taplin ME, Choudhury AD, Pomerantz MM, Bellmunt J, Yu C, Sun Z, Srinivas S, Kantoff PW, Sweeney CJ, Harshman LC. Tripathi A, et al. Among authors: sweeney cj. Clin Cancer Res. 2020 Dec 1;26(23):6122-6131. doi: 10.1158/1078-0432.CCR-20-2306. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943461 Free PMC article. Clinical Trial.
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).
ICECaP Working Group; Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, Li S, Philipson T, Buyse M, Halabi S, Kantoff P, Sartor AO, Soule H, Mahal B. ICECaP Working Group, et al. Among authors: sweeney c. J Natl Cancer Inst. 2015 Sep 25;107(12):djv261. doi: 10.1093/jnci/djv261. Print 2015 Dec. J Natl Cancer Inst. 2015. PMID: 26409187 Free PMC article.
1,186 results